nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—ADRA2C—attention deficit hyperactivity disorder	0.204	0.253	CbGaD
Paliperidone—DRD4—attention deficit hyperactivity disorder	0.11	0.137	CbGaD
Paliperidone—HTR1B—attention deficit hyperactivity disorder	0.0981	0.122	CbGaD
Paliperidone—DRD3—attention deficit hyperactivity disorder	0.0952	0.118	CbGaD
Paliperidone—DRD1—attention deficit hyperactivity disorder	0.0935	0.116	CbGaD
Paliperidone—ADRA2A—attention deficit hyperactivity disorder	0.0868	0.108	CbGaD
Paliperidone—DRD2—attention deficit hyperactivity disorder	0.0659	0.0819	CbGaD
Paliperidone—HTR2A—attention deficit hyperactivity disorder	0.0509	0.0633	CbGaD
Paliperidone—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00341	0.0869	CbGeAlD
Paliperidone—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00181	0.0462	CbGeAlD
Paliperidone—DRD1—forebrain—attention deficit hyperactivity disorder	0.00108	0.0276	CbGeAlD
Paliperidone—Risperidone—ADRA2C—attention deficit hyperactivity disorder	0.000991	0.139	CrCbGaD
Paliperidone—Iloperidone—ADRA2C—attention deficit hyperactivity disorder	0.000929	0.13	CrCbGaD
Paliperidone—DRD4—brain—attention deficit hyperactivity disorder	0.000894	0.0228	CbGeAlD
Paliperidone—HTR1B—forebrain—attention deficit hyperactivity disorder	0.000878	0.0224	CbGeAlD
Paliperidone—HTR1D—forebrain—attention deficit hyperactivity disorder	0.000851	0.0217	CbGeAlD
Paliperidone—HTR2C—forebrain—attention deficit hyperactivity disorder	0.000842	0.0215	CbGeAlD
Paliperidone—DRD3—nervous system—attention deficit hyperactivity disorder	0.000822	0.0209	CbGeAlD
Paliperidone—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000791	0.0202	CbGeAlD
Paliperidone—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.000743	0.0189	CbGeAlD
Paliperidone—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.000719	0.0183	CbGeAlD
Paliperidone—DRD1—midbrain—attention deficit hyperactivity disorder	0.000716	0.0182	CbGeAlD
Paliperidone—HTR1A—forebrain—attention deficit hyperactivity disorder	0.000709	0.0181	CbGeAlD
Paliperidone—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000653	0.0167	CbGeAlD
Paliperidone—DRD2—forebrain—attention deficit hyperactivity disorder	0.000641	0.0163	CbGeAlD
Paliperidone—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000631	0.0161	CbGeAlD
Paliperidone—DRD3—brain—attention deficit hyperactivity disorder	0.000628	0.016	CbGeAlD
Paliperidone—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000608	0.0155	CbGeAlD
Paliperidone—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.000599	0.0153	CbGeAlD
Paliperidone—DRD1—nervous system—attention deficit hyperactivity disorder	0.000589	0.015	CbGeAlD
Paliperidone—HTR1B—midbrain—attention deficit hyperactivity disorder	0.00058	0.0148	CbGeAlD
Paliperidone—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000567	0.0144	CbGeAlD
Paliperidone—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000562	0.0143	CbGeAlD
Paliperidone—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000556	0.0142	CbGeAlD
Paliperidone—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000553	0.0141	CbGeAlD
Paliperidone—Risperidone—DRD4—attention deficit hyperactivity disorder	0.000537	0.0753	CrCbGaD
Paliperidone—HRH1—forebrain—attention deficit hyperactivity disorder	0.000506	0.0129	CbGeAlD
Paliperidone—Iloperidone—DRD4—attention deficit hyperactivity disorder	0.000504	0.0706	CrCbGaD
Paliperidone—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000497	0.0127	CbGeAlD
Paliperidone—ADRA1B—brain—attention deficit hyperactivity disorder	0.000483	0.0123	CbGeAlD
Paliperidone—Risperidone—HTR1B—attention deficit hyperactivity disorder	0.000477	0.0669	CrCbGaD
Paliperidone—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000477	0.0122	CbGeAlD
Paliperidone—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000468	0.0119	CbGeAlD
Paliperidone—Risperidone—DRD3—attention deficit hyperactivity disorder	0.000463	0.0649	CrCbGaD
Paliperidone—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000462	0.0118	CbGeAlD
Paliperidone—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000459	0.0117	CbGeAlD
Paliperidone—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000457	0.0117	CbGeAlD
Paliperidone—Risperidone—DRD1—attention deficit hyperactivity disorder	0.000455	0.0637	CrCbGaD
Paliperidone—DRD1—brain—attention deficit hyperactivity disorder	0.00045	0.0115	CbGeAlD
Paliperidone—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000445	0.0113	CbGeAlD
Paliperidone—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.00044	0.0112	CbGeAlD
Paliperidone—Iloperidone—DRD3—attention deficit hyperactivity disorder	0.000435	0.0609	CrCbGaD
Paliperidone—Iloperidone—DRD1—attention deficit hyperactivity disorder	0.000427	0.0598	CrCbGaD
Paliperidone—DRD2—midbrain—attention deficit hyperactivity disorder	0.000423	0.0108	CbGeAlD
Paliperidone—Risperidone—ADRA2A—attention deficit hyperactivity disorder	0.000423	0.0592	CrCbGaD
Paliperidone—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000422	0.0108	CbGeAlD
Paliperidone—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000411	0.0105	CbGeAlD
Paliperidone—Iloperidone—ADRA2A—attention deficit hyperactivity disorder	0.000396	0.0555	CrCbGaD
Paliperidone—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000385	0.00981	CbGeAlD
Paliperidone—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000385	0.00981	CbGeAlD
Paliperidone—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000371	0.00944	CbGeAlD
Paliperidone—HTR1B—brain—attention deficit hyperactivity disorder	0.000365	0.00929	CbGeAlD
Paliperidone—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000362	0.00923	CbGeAlD
Paliperidone—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000357	0.0091	CbGeAlD
Paliperidone—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000355	0.00904	CbGeAlD
Paliperidone—HTR1D—brain—attention deficit hyperactivity disorder	0.000353	0.00899	CbGeAlD
Paliperidone—HTR2C—brain—attention deficit hyperactivity disorder	0.000349	0.0089	CbGeAlD
Paliperidone—DRD2—nervous system—attention deficit hyperactivity disorder	0.000348	0.00886	CbGeAlD
Paliperidone—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000342	0.0087	CbGeAlD
Paliperidone—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000338	0.00861	CbGeAlD
Paliperidone—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000335	0.00853	CbGeAlD
Paliperidone—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000334	0.00851	CbGeAlD
Paliperidone—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000328	0.00836	CbGeAlD
Paliperidone—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000327	0.00834	CbGeAlD
Paliperidone—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000325	0.00829	CbGeAlD
Paliperidone—Risperidone—DRD2—attention deficit hyperactivity disorder	0.000321	0.0449	CrCbGaD
Paliperidone—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000318	0.00811	CbGeAlD
Paliperidone—Iloperidone—DRD2—attention deficit hyperactivity disorder	0.000301	0.0421	CrCbGaD
Paliperidone—HTR1A—brain—attention deficit hyperactivity disorder	0.000294	0.0075	CbGeAlD
Paliperidone—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000279	0.00711	CbGeAlD
Paliperidone—HRH1—nervous system—attention deficit hyperactivity disorder	0.000275	0.007	CbGeAlD
Paliperidone—ADRA1A—brain—attention deficit hyperactivity disorder	0.000271	0.00691	CbGeAlD
Paliperidone—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.00027	0.00687	CbGeAlD
Paliperidone—DRD2—brain—attention deficit hyperactivity disorder	0.000266	0.00677	CbGeAlD
Paliperidone—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000264	0.00674	CbGeAlD
Paliperidone—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.00026	0.00662	CbGeAlD
Paliperidone—ADRA2C—brain—attention deficit hyperactivity disorder	0.000258	0.00658	CbGeAlD
Paliperidone—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000254	0.00647	CbGeAlD
Paliperidone—Risperidone—HTR2A—attention deficit hyperactivity disorder	0.000248	0.0347	CrCbGaD
Paliperidone—Iloperidone—HTR2A—attention deficit hyperactivity disorder	0.000232	0.0326	CrCbGaD
Paliperidone—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000229	0.00584	CbGeAlD
Paliperidone—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000221	0.00563	CbGeAlD
Paliperidone—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000216	0.0055	CbGeAlD
Paliperidone—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000212	0.00541	CbGeAlD
Paliperidone—HRH1—brain—attention deficit hyperactivity disorder	0.00021	0.00535	CbGeAlD
Paliperidone—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000209	0.00532	CbGeAlD
Paliperidone—ADRA2A—brain—attention deficit hyperactivity disorder	0.000206	0.00525	CbGeAlD
Paliperidone—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000204	0.00521	CbGeAlD
Paliperidone—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000201	0.00513	CbGeAlD
Paliperidone—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000197	0.00501	CbGeAlD
Paliperidone—HTR2A—brain—attention deficit hyperactivity disorder	0.000175	0.00447	CbGeAlD
Paliperidone—CYP2D6—brain—attention deficit hyperactivity disorder	0.00016	0.00407	CbGeAlD
Paliperidone—DRD2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.29e-05	8.67e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.29e-05	8.66e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.28e-05	8.6e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.28e-05	8.59e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.28e-05	8.57e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.27e-05	8.53e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.27e-05	8.52e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.27e-05	8.51e-05	CbGpPWpGaD
Paliperidone—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.27e-05	8.51e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.27e-05	8.51e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.26e-05	8.43e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.26e-05	8.41e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.25e-05	8.41e-05	CbGpPWpGaD
Paliperidone—DRD4—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.25e-05	8.38e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.25e-05	8.37e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.25e-05	8.35e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.24e-05	8.31e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.24e-05	8.29e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.24e-05	8.28e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	1.23e-05	8.21e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.23e-05	8.21e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.22e-05	8.18e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.22e-05	8.16e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.21e-05	8.14e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.21e-05	8.12e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.21e-05	8.12e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.21e-05	8.12e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.21e-05	8.08e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	1.21e-05	8.08e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.2e-05	8.05e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.2e-05	8.03e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.2e-05	8.02e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.2e-05	8.02e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.2e-05	8.01e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.2e-05	8.01e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.19e-05	8e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.19e-05	7.98e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.18e-05	7.92e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.18e-05	7.91e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.18e-05	7.9e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.18e-05	7.9e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.18e-05	7.88e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.18e-05	7.88e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.17e-05	7.86e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.17e-05	7.83e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.17e-05	7.81e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.16e-05	7.8e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.16e-05	7.78e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.16e-05	7.76e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.15e-05	7.73e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.15e-05	7.73e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.14e-05	7.64e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.14e-05	7.61e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.13e-05	7.6e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.13e-05	7.55e-05	CbGpPWpGaD
Paliperidone—DRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.13e-05	7.54e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.12e-05	7.51e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.11e-05	7.44e-05	CbGpPWpGaD
Paliperidone—DRD3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.11e-05	7.44e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.1e-05	7.36e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.09e-05	7.33e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.09e-05	7.31e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.09e-05	7.28e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.08e-05	7.26e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.08e-05	7.25e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.08e-05	7.24e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.08e-05	7.23e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.08e-05	7.21e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.07e-05	7.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.06e-05	7.11e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.06e-05	7.09e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.06e-05	7.09e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.06e-05	7.09e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.06e-05	7.09e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.04e-05	7e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.04e-05	7e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.04e-05	6.98e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.04e-05	6.97e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.04e-05	6.94e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.02e-05	6.85e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.01e-05	6.76e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.01e-05	6.75e-05	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1e-05	6.72e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	9.95e-06	6.67e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.95e-06	6.67e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.94e-06	6.66e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9.92e-06	6.65e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	9.86e-06	6.61e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.8e-06	6.56e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	9.79e-06	6.56e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.73e-06	6.52e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.71e-06	6.51e-05	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.68e-06	6.49e-05	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.63e-06	6.45e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.58e-06	6.42e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.53e-06	6.39e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.43e-06	6.32e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.4e-06	6.29e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.37e-06	6.28e-05	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.37e-06	6.28e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.33e-06	6.25e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.26e-06	6.2e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.25e-06	6.19e-05	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.22e-06	6.18e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9.15e-06	6.13e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.13e-06	6.12e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.12e-06	6.11e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	9.12e-06	6.11e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.11e-06	6.1e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.11e-06	6.1e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.1e-06	6.1e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.06e-06	6.07e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9e-06	6.03e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.98e-06	6.02e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	8.97e-06	6.01e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.81e-06	5.9e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.81e-06	5.9e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.79e-06	5.89e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.77e-06	5.87e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.74e-06	5.86e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.67e-06	5.81e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.62e-06	5.78e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.51e-06	5.7e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.51e-06	5.7e-05	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.5e-06	5.69e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.49e-06	5.69e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.46e-06	5.67e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.42e-06	5.64e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	8.41e-06	5.63e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.37e-06	5.61e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.35e-06	5.59e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.34e-06	5.59e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.34e-06	5.59e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.24e-06	5.52e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.2e-06	5.49e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.19e-06	5.49e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.19e-06	5.49e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.19e-06	5.49e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.16e-06	5.46e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.06e-06	5.4e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.06e-06	5.4e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.02e-06	5.37e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.99e-06	5.36e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.96e-06	5.33e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.96e-06	5.33e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.93e-06	5.31e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.92e-06	5.3e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.87e-06	5.27e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	7.85e-06	5.26e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.85e-06	5.26e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.81e-06	5.23e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.8e-06	5.22e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.72e-06	5.17e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.7e-06	5.16e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.7e-06	5.16e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.68e-06	5.15e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.67e-06	5.14e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.61e-06	5.1e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.58e-06	5.08e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.58e-06	5.08e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.44e-06	4.98e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.43e-06	4.98e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	7.42e-06	4.97e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.41e-06	4.97e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.38e-06	4.94e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	7.37e-06	4.94e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.31e-06	4.9e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.3e-06	4.89e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.29e-06	4.88e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.2e-06	4.82e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.17e-06	4.81e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.16e-06	4.8e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.16e-06	4.79e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.08e-06	4.74e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.08e-06	4.74e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.07e-06	4.73e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.06e-06	4.73e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.99e-06	4.68e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.96e-06	4.66e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.96e-06	4.66e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.95e-06	4.65e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.94e-06	4.65e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.93e-06	4.65e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.91e-06	4.63e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.88e-06	4.61e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.86e-06	4.6e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.82e-06	4.57e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.82e-06	4.57e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.73e-06	4.51e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.71e-06	4.49e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.65e-06	4.46e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.49e-06	4.34e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	6.49e-06	4.34e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.44e-06	4.32e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.4e-06	4.29e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.39e-06	4.28e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	6.38e-06	4.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	6.38e-06	4.27e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.27e-06	4.2e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.26e-06	4.19e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.14e-06	4.12e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.04e-06	4.05e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	6.03e-06	4.04e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	5.99e-06	4.01e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.96e-06	3.99e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.93e-06	3.97e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.83e-06	3.9e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	5.53e-06	3.7e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	5.49e-06	3.68e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.38e-06	3.6e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.19e-06	3.48e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.18e-06	3.47e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.17e-06	3.46e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.02e-06	3.37e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.95e-06	3.31e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.94e-06	3.31e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.56e-06	3.05e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.48e-06	3e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.39e-06	2.94e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	4.24e-06	2.84e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.24e-06	2.84e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	4.17e-06	2.79e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.08e-06	2.73e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	3.93e-06	2.63e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	3.9e-06	2.61e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.88e-06	2.6e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.69e-06	2.47e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.61e-06	2.42e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.55e-06	2.38e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.39e-06	2.27e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.23e-06	2.16e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.2e-06	2.14e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	3.18e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.16e-06	2.11e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.85e-06	1.91e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.75e-06	1.84e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.74e-06	1.83e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.66e-06	1.78e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.62e-06	1.76e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	2.59e-06	1.73e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	2.57e-06	1.72e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	2.55e-06	1.71e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.42e-06	1.62e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.38e-06	1.59e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.37e-06	1.59e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	2.37e-06	1.59e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.33e-06	1.56e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.16e-06	1.45e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.69e-06	1.13e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.1e-06	7.38e-06	CbGpPWpGaD
